297 biotech venture capital firms in the US
We list 297 biotech venture capital firms in the US as of November 2026: 294 have an SEC filing on file and 3 were checked on the firm's own website or an official register, and the list was last checked on 6 Nov 2026. The cities with the most head offices on this list are San Francisco (27), New York (23) and Boston (19).
Top 10 biotech venture capital firms in the US, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (15) and completeness of the public record (10). Regional focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
SR One
Type: VC firm · HQ: Wayne, PA · Focus: Biotech, Healthtech · Latest activity: New fund, Sep 2026 · Fund size on file: $600M (SEC Form D, 2024)
Latest fund filing dated Sep 2026; $600M fund on file (SEC Form D, 2024); 100% of its observed portfolio is biotech and life sciences; names the US as where it invests; 8 named decision-makers on file.
Hatteras Venture Partners
Type: VC firm · HQ: Durham, NC · Stages: Seed · Focus: Biotech, Healthtech, Medtech · Latest activity: New fund, Oct 2026 · Fund size on file: $250M (SEC Form D, 2023)
Latest fund filing dated Oct 2026; $250M fund on file (SEC Form D, 2023); 62% of its observed portfolio is biotech and life sciences; names the US as where it invests; 8 named decision-makers on file.
First In Ventures
Type: VC firm · HQ: Hobe Sound, FL · Stages: Pre-seed, Seed · Focus: Biotech, Healthtech, AI, Climate Tech · Latest activity: New fund, Sep 2026 · Fund size on file: $22M (SEC Form D, 2026)
Latest fund filing dated Sep 2026; $22M fund on file (SEC Form D, 2026); 69% of its observed portfolio is biotech and life sciences; names the US as where it invests; 5 named decision-makers on file.
AMR Action Fund
Type: VC firm · HQ: Boston, MA · Focus: Biotech, Healthtech, Media, Medtech · Latest activity: Portfolio news, Aug 2026 · Private fund assets: $977M (SEC Form ADV)
Portfolio news dated Aug 2026; $977M on file (SEC Form ADV); 82% of its observed portfolio is biotech and life sciences; names the US as where it invests; 1 named decision-maker on file.
Longitude Venture Partners
Type: VC firm · HQ: Menlo Park, CA · Stages: Growth · Focus: Biotech, Healthtech, Medtech · Latest activity: New deal, Jun 2026 · Fund size on file: $600M (SEC Form D, 2022)
Dated new deal in Jun 2026; $600M fund on file (SEC Form D, 2022); 80% of its observed portfolio is biotech and life sciences; names the US as where it invests; 8 named decision-makers on file.
Digitalis Ventures
Type: VC firm · HQ: New York, NY · Stages: Seed · Focus: Biotech, Healthtech, Medtech · Latest activity: Portfolio news, Nov 2026 · Private fund assets: $862M (SEC Form ADV)
Portfolio news dated Nov 2026; $862M on file (SEC Form ADV); states biotech and life sciences as a focus; names the US as where it invests; 8 named decision-makers on file.
Cancer Focus Fund
Type: VC firm · HQ: Shreveport, LA · Focus: Biotech, Healthtech · Latest activity: New fund, May 2026 · Private fund assets: $148M (SEC Form ADV)
Latest fund filing dated May 2026; $148M on file (SEC Form ADV); 100% of its observed portfolio is biotech and life sciences; names the US as where it invests; 5 named decision-makers on file.
Madrona
Type: VC firm · HQ: Seattle, WA · Stages: Pre-seed, Seed, Series A, Series B, Growth · Focus: Biotech, AI, Consumer, Deep Tech · Latest activity: New deal, Oct 2026 · Fund size on file: $490M (SEC Form D, 2025)
Dated new deal in Oct 2026; $490M fund on file (SEC Form D, 2025); states biotech and life sciences as a focus; names the US as where it invests; 8 named decision-makers on file.
Gore Range Capital
Type: VC firm · HQ: Southlake, TX · Stages: Seed · Focus: Biotech, Healthtech, Medtech · Latest activity: New deal, Aug 2026 · Fund size on file: $250M (SEC Form D, 2026)
Dated new deal in Aug 2026; $250M fund on file (SEC Form D, 2026); states biotech and life sciences as a focus; names the US as where it invests; 1 named decision-maker on file.
Vida Ventures
Type: VC firm · HQ: Los Angeles, CA · Focus: Biotech, Healthtech · Latest activity: New fund, Sep 2026 · Fund size on file: $750M (SEC Form D, 2021)
Latest fund filing dated Sep 2026; $750M fund on file (SEC Form D, 2021); 100% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
First 25 of 297 biotech venture capital firms in the US
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| SR One | VC firm | Wayne, PA | Biotech, Healthtech | New fund, Sep 2026 | $600M (SEC Form D, 2024) | 4 Nov 2026 | 8 names · Unlock | |
| Hatteras Venture Partners | VC firm | Durham, NC | Seed | Biotech, Healthtech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2023) | 4 Nov 2026 | 8 names · Unlock |
| First In Ventures | VC firm | Hobe Sound, FL | Pre-seed, Seed | Biotech, Healthtech, AI, Climate Tech | New fund, Sep 2026 | $22M (SEC Form D, 2026) | 4 Nov 2026 | 5 names, firm email · Unlock |
| AMR Action Fund | VC firm | Boston, MA | Biotech, Healthtech, Media, Medtech | Portfolio news, Aug 2026 | $977M (SEC Form ADV) | 5 Nov 2026 | 1 name · Unlock | |
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Biotech, Healthtech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 5 Nov 2026 | 8 names · Unlock |
| Digitalis Ventures | VC firm | New York, NY | Seed | Biotech, Healthtech, Medtech | Portfolio news, Nov 2026 | $862M (SEC Form ADV) | 5 Nov 2026 | 8 names, firm email · Unlock |
| Cancer Focus Fund | VC firm | Shreveport, LA | Biotech, Healthtech | New fund, May 2026 | $148M (SEC Form ADV) | 5 Nov 2026 | 5 names · Unlock | |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| Gore Range Capital | VC firm | Southlake, TX | Seed | Biotech, Healthtech, Medtech | New deal, Aug 2026 | $250M (SEC Form D, 2026) | 4 Nov 2026 | 1 name, firm email · Unlock |
| Vida Ventures | VC firm | Los Angeles, CA | Biotech, Healthtech | New fund, Sep 2026 | $750M (SEC Form D, 2021) | 4 Nov 2026 | 8 names, firm email · Unlock | |
| SOSV | VC firm | United States | Pre-seed | Biotech, Deep Tech, Climate Tech, Healthtech | Portfolio news, Nov 2026 | $131M (SEC Form D, 2022) | 4 Nov 2026 | 8 names · Unlock |
| ARCH Venture Partners | VC firm | Chicago, IL | Pre-seed, Seed | Biotech, Healthtech, Deep Tech | New fund, Aug 2026 | $3.0B (SEC Form D, 2024) | 4 Nov 2026 | 8 names · Unlock |
| Narya | VC firm | Columbus, OH | Seed | Biotech, Fintech, Healthtech, Defense Tech | New fund, Sep 2026 | $200M (SEC Form D, 2026) | 4 Nov 2026 | 1 name · Unlock |
| TCGX | VC firm | Palo Alto, CA | Biotech, Healthtech | New fund, Oct 2026 | $600M (SEC Form D, 2026) | 4 Nov 2026 | 8 names, firm email · Unlock | |
| Bison Ventures | VC firm | San Francisco, CA | Pre-seed, Seed, Series A, Series B | Biotech, AI, Healthtech, Energy | New fund, Oct 2026 | $160M (SEC Form D, 2025) | 4 Nov 2026 | 2 names, firm email · Unlock |
| NSV | VC firm | Greenwich, CT | Seed, Late stage | Biotech, Healthtech, AI, Semiconductor | Portfolio news, Oct 2026 | $990M (SEC Form ADV) | 5 Nov 2026 | 5 names · Unlock |
| Clarevia | VC firm | Madison, WI | Biotech, Healthtech, Medtech | New deal, May 2026 | $100M (SEC Form D, 2023) | 5 Nov 2026 | 8 names · Unlock | |
| Mitsui & Co. Global Investment, Inc. | Corporate VC | Menlo Park, CA | Biotech, Healthtech, AI, Industrial Tech | Portfolio news, Jun 2026 | $142M (SEC Form ADV) | 5 Nov 2026 | 3 names · Unlock | |
| Safar Partners | VC firm | Cambridge, MA | Seed | Biotech, Healthtech, Industrial Tech, Deep Tech | New deal, Aug 2026 | $300M (SEC Form D, 2023) | 4 Nov 2026 | 3 names, firm email · Unlock |
| Felicis | VC firm | Menlo Park, CA | Seed, Series A | Biotech, AI, Developer Tools, Healthtech | New deal, Oct 2026 | $900M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| 8VC | VC firm | Austin, TX | Biotech, Data, AI, Healthtech | New deal, Oct 2026 | $400M (SEC Form D, 2026) | 4 Nov 2026 | 8 names · Unlock | |
| True Ventures | VC firm | Palo Alto, CA | Pre-seed, Seed | Biotech, AI, Fintech, Deep Tech | New fund, Sep 2026 | $800M (SEC Form D, 2022) | 4 Nov 2026 | 8 names · Unlock |
| HOF Capital | VC firm | New York, NY | Any stage | Biotech, AI, Fintech, Consumer | New fund, Aug 2026 | $300M (SEC Form D, 2021) | 4 Nov 2026 | 2 names · Unlock |
| Battery Ventures | VC firm | Boston, MA | Any stage | Biotech, Energy, Future of Work, Data | Portfolio news, Jul 2026 | $3.2B (own site) | 4 Nov 2026 | LinkedIn page · Unlock |
| Transpose Platform | VC firm | Houston, TX | Pre-seed | Biotech, AI, Generalist | New fund, Sep 2026 | $500M (SEC Form D, 2026) | 4 Nov 2026 | 8 names · Unlock |
You are seeing 25 of 297. The full list adds 272 more firms and 1,473 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 297 break down
By US state
| US state | On this list | Share |
|---|---|---|
| California | 107 | 36% |
| Massachusetts | 37 | 12% |
| New York | 28 | 9% |
| Texas | 23 | 8% |
| Florida | 15 | 5% |
| Washington | 7 | 2% |
| Illinois | 7 | 2% |
| Connecticut | 7 | 2% |
| Maryland | 5 | 2% |
| Pennsylvania | 4 | 1% |
Full lists, each with its own row count: Biotech investors in California (108)Biotech investors in Massachusetts (37)Biotech investors in New York (29)Biotech investors in Texas (23)Biotech investors in Florida (15)
By stage
| Stage | On this list | Share |
|---|---|---|
| Pre-Seed | 79 | 27% |
| Seed | 158 | 53% |
| Series A | 58 | 20% |
| Series B | 32 | 11% |
| Growth | 42 | 14% |
Stage is our research. A firm can back more than one stage.
Full lists, each with its own row count: Pre-seed biotech investors in the US (81)Seed biotech investors in the US (159)Series A biotech investors in the US (59)Series B biotech investors in the US (34)Growth-stage biotech investors in the US (44)
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 292 | 98% |
| Corporate VC | 4 | 1% |
Method and limits
- Source
- 294 of the 297 rows carry an SEC filing (Form D or Form ADV). 289 of the 297 have a website we checked; the other 8 rest on the filing or register entry alone. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. This list holds VC firms, fund managers and corporate venture arms; accelerators and angel networks are in their own lists. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (15) and completeness of the public record (10). Regional focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 6 Nov 2026.
- Fill rates
- Of 297 rows: stage 214, sector 297, fund size 268, website 289. In the paid file: named decision-makers on 278 rows, firm email on 92, LinkedIn page on 134, check size on 12.
- Corrections
- Email [email protected] or use the update form. We act within 5 working days.
Questions
How many biotech venture capital firms in the US are there?
We list 297 as of November 2026. 166 of the 297 have a fund filing or a dated deal in the last 12 months. The cities with the most are San Francisco (27), New York (23) and Boston (19).
Which biotech venture capital firms in the US raised a new fund in the last 12 months?
108 of the 297 have a fund filing dated in the last 12 months. The most recent on this list are Hyve Ventures (Nov 2026), Future Ventures (Oct 2026) and Draper Associates (Oct 2026).
What is the typical fund size of biotech venture capital firms in the US?
The median fund size on file for this list is $81M, across the 198 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 99 do not disclose a size there.
Which stage do most biotech venture capital firms in the US back?
Of the 214 with a stage on file, seed (158), pre-seed (79) and Series A (58). A firm can back more than one stage, and 83 rows have no stage on file yet.
Where does the data on biotech venture capital firms in the US come from and how often is it updated?
294 of the 297 rows have an SEC filing on file (Form D or Form ADV) and 3 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 6 Nov 2026 at the latest. The whole file is re-verified twice a year.
Can I download the list of biotech venture capital firms in the US as a spreadsheet?
Yes. The file holds all 297 rows in Excel and CSV, with 1,473 named decision-makers and 92 firm emails, for $49 one-time. 25 rows are free on this page.
Narrower lists
Seed biotech investors in the US (159)Biotech investors in California (108)Biotech investors in the San Francisco Bay Area (88)Pre-seed biotech investors in the US (81)Series A biotech investors in the US (59)Biotech investors in Silicon Valley (48)Growth-stage biotech investors in the US (44)Biotech investors in Massachusetts (37)Series B biotech investors in the US (34)Biotech investors in New York (29)Biotech investors in Texas (23)Biotech investors in Florida (15)
Related lists
CPG venture capital firms in the US (130)Consumer venture capital firms in the US (348)Ecommerce venture capital firms in the US (69)Edtech venture capital firms in the US (83)Proptech venture capital firms in the US (96)Climate tech venture capital firms in the US (256)Deep tech venture capital firms in the US (322)Hardware venture capital firms in the US (272)Impact venture capital firms in the US (55)Food and beverage venture capital firms in the US (91)AI venture capital firms in the US (1,112)SaaS venture capital firms in the US (1,049)Healthtech venture capital firms in the US (709)Fintech venture capital firms in the US (525)Medtech venture capital firms in the US (350)Industrial tech venture capital firms in the US (267)B2B venture capital firms in the US (257)Energy venture capital firms in the US (249)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to biotech and life sciences and the US. Guide: how to build an investor list. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.